Home > Insider Trading > Filing (0000950170-24-062009)

Filing Details

Accession Number:: 0000950170-24-062009
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-05-17 18:42:21
Reporting Period:: 2024-05-17

Accepted Time:: 2024-05-17 18:42:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1820190	Scilex Holding Co	SCLX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1470981	Henry Ji	C/O Scilex Holding Company 960 San Antonio Road Palo Alto CA 94303	Executive Chairperson	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-05-17	50,000	$0.88	50,070	No	4	P	Indirect	By BioVintage, Inc.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By BioVintage, Inc.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,749	Indirect	By BioVintage, Inc.
Common Stock	305,273	Direct
Common Stock	292,264	Indirect	See Footnote
Common Stock	5,640	Indirect	By Spouse

Footnotes

Open market purchase by the reporting person of 50,000 shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock reported represents an aggregate number of shares purchased in multiple open market transactions over a range of sales prices.
Reflects the weighted average price of the shares of Common Stock purchased on the open market in multiple transactions on May 17, 2024 at prices ranging from $0.8700 to $0.8800 per share, inclusive. The amount reflected has been rounded to 4 decimal points.
The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of such shares of Common Stock purchased at each separate price within such range.
On December 30, 2022, the Board of Directors of Sorrento Therapeutics, Inc. ("Sorrento") declared a stock dividend (the "Dividend") to all holders of record of its common stock as of the close of business on January 9, 2023, of 0.1410127 of a share of Common Stock for each one share of common stock, par value $0.0001 per share, of Sorrento ("Sorrento Common Stock"). The reporting person wrote a put option in Sorrento Common Stock on August 26, 2022 (the "Put Option"), which was adjusted as a result of the Stock Dividend to relate to an aggregate of 19,500 shares of Sorrento Common Stock and 2,749 shares of Common Stock and to reflect a corresponding change to the exercise price of the Put Option to $0.80268 per share of Sorrento Common Stock and $8.6002 per share of Common Stock.
(Continued from footnote 4 ) The Put Option settled on March 17, 2023 and resulted in the reporting person becoming entitled to receive 2,749 shares of Common Stock at a price of $8.6002 per share of Common Stock, upon the expiration of the lock-up on such shares which is currently set to expire on September 30, 2024.
Shares are held in family trusts of which the reporting person is a co-trustee with his spouse.